Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE In this study we demonstrate that IFNalpha treatment of the two myeloma cell lines, U266-1984 and U-1958, results in the decrease of STAT3 activity as demonstrated by a diminished STAT3/3 DNA-binding activity and the shift from STAT3/3 towards STAT1/1 and STAT3/1 complexes in EMSA, leading to the down-regulation of known STAT3 target genes such as Bcl-X(L), Mcl-1 and survivin. 17880940 2007
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 Biomarker disease BEFREE Highly expressed genes in MM cells included cell survival pathway genes such as mcl-1, dad-1, caspase 8, and FADD-like apoptosis regulator (FLIP); oncogenes/transcriptional factors such as Jun-D, Xbp-1, calmodulin, Calnexin, and FGFR-3; stress response and ubiquitin/proteasome pathway-related genes and various ribosomal genes reflecting increased metabolic and translational activity. 12969976 2004
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE Nuclear topography of the 1q21 genomic region and Mcl-1 protein levels associated with pathophysiology of multiple myeloma. 19580342 2009
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE Adherence of MM cells to bone marrow stromal cells (BMSCs) induced increased Mcl-1 expression associated with signal transducer and activator of transcription 3 (STAT3) phosphorylation, which was inhibited in a time- and dose-dependent manner by seliciclib. 15827128 2005
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 Biomarker disease BEFREE This work led to the discovery of <b>1</b>, a potent Mcl-1 inhibitor (IC<sub>50</sub> = 19 nM in an OPM-2 cell viability assay) with good pharmacokinetic properties and excellent in vivo efficacy in an OPM-2 multiple myeloma xenograft model. 31736296 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 Biomarker disease BEFREE In conclusion, our data demonstrate that soluble factors from MM cells are able to generate MDSC through Mcl-1 upregulation and this cell population can be considered as a possible target in MM disease. 25871384 2015
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE GRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation associated with reduction in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells. 19996089 2010
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 PosttranslationalModification disease BEFREE Co-culture experiments resulted in MDSC-induced AMPK phosphorylation in MM cells, which was associated with an increase in the anti-apoptotic factors MCL-1 and BCL-2, and the autophagy-marker LC3II. 30419344 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE IHC of multiple myeloma patient bone marrow biopsies and aspirates (n = 95) revealed high levels of BCL-2 and BCL-XL in 62% and 43% of evaluable samples, respectively, while 34% were characterized as BCL-2(High)/BCL-XL (Low) In addition to MCL-1, our data suggest that BCL-XL may also be a potential resistance factor to venetoclax monotherapy and in combination with bortezomib. 26939706 2016
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 Biomarker disease BEFREE Taken together, we conclude that bortezomib-induced apoptosis in ATLL and CTCL cells at least partly depends on the upregulation of Noxa and functional repression of Mcl-1, as is also the case in MM and malignant melanoma. 19068089 2009
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE B- and mantle-cell lymphomas, chronic myeloid leukaemia, and multiple myeloma, however, express abnormally high levels of MCL1, contributing to chemoresistance and disease relapse. 20023629 2010
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 Biomarker disease BEFREE Levels of MYC and myeloid cell leukemia 1, two known eIF4F-responsive transcripts and key survival factors in MM, were reduced upon eIF4F inhibition, and their independent suppression also synergized with DEX. 25197055 2014
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE We found that lovastatin induced apoptosis in myeloma and lymphoma cells by inhibition of geranylgeranylation and subsequent down regulation of Mcl-1, probably the most important anti-apoptotic protein in myeloma. 16454747 2006
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE We also show that PK1 upregulates Mcl-1 expression in a time- and dose-dependent manner in human MM cell lines and in the cells of patients with MM. 20795791 2010
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE We showed that ectopic MCL1 expression rescued apoptosis of MM. 31653349 2020
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 Biomarker disease BEFREE Usp24 was found to sustain myeloma cell survival and Mcl-1 regulation in the absence of Usp9x. 25814533 2015
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 Biomarker disease BEFREE Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. 31320555 2020
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE Ritonavir and metformin effectively suppressed AKT and mTORC1 phosphorylation and prosurvival BCL-2 family member MCL-1 expression in multiple myeloma cell lines in vitro and in vivo. 25542900 2015
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE Our results indicate that the myeloma cell survival activity of IL-6 linked to Bcl-xL regulation cannot be generalized and emphasize that Mcl-1 is the main target of IL-6 and IFN-alpha stimulation. 11175262 2000
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 Biomarker disease BEFREE These findings underscore the implication of the Mcl-1/Bak axis in myeloma cell death triggered by Thapsigargin. 27697610 2016
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 Biomarker disease BEFREE Multiple myeloma cell survival is highly dependent on Mcl-1 antiapoptotic molecules. 17545623 2007
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 Biomarker disease BEFREE Here we discuss the regulation and function of Mcl-1 in the pathophysiology of multiple myeloma. 15467463 2004
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE Treatment of MM cell lines with P276-00 resulted in apoptosis that correlated with transcription inhibition and a significant decline in Mcl-1 protein levels with the appearance of cleaved PARP in these cells. 21216463 2011
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 Biomarker disease BEFREE Furthermore, previous studies demonstrated that proteasome inhibitors induce Mcl-1 accumulation that, in turn, slows down their pro-apoptotic effects, and the cell survival in multiple myeloma is highly dependent on Mcl-1. 25812695 2015
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.400 AlteredExpression disease BEFREE In myeloma, in vitro sensitivity to venetoclax is mainly observed in plasma cells harboring the t(11;14) translocation, a molecular subgroup associated with high Bcl-2 and low Mcl-1/Bcl-XL expression. 30076373 2018